When the FDA approved fezolinetant for treating moderate to severe hot flashes in menopausal women, the news made headlines. At last, a non-hormonal option that worked by targeting the brain’s ...

WASHINGTON — U.S. health regulators on Friday approved a new type of drug for women dealing with uncomfortable hot flashes caused by menopause. The Food and Drug Administration approved the once ...

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

The U.S. Food and Drug Administration has extended its review of Bayer's experimental menopause relief drug, the German ...

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and ...

“It’s going to reduce hot flashes, they say, in over 50% of women, reduce them by 50%. If those numbers are accurate, this is going to be a wonder drug.” ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

The FDA on May 12 approved Astellas’ Veozah — a once-a-day pill meant to treat hot flashes associated with menopause. The drug is an alternative to hormone replacement therapies typically used ...

Until recently, there was only one FDA-approved nonhormonal medication for hot flashes, an SSRI called Brisdelle, which contains paroxetine in a lower dose than the antidepressant drug Paxil.